Octagon Capital Advisors LP Sells 79,000 Shares of Abivax SA Sponsored ADR $ABVX

Octagon Capital Advisors LP reduced its position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 10.4% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 677,000 shares of the company’s stock after selling 79,000 shares during the period. Abivax comprises 8.3% of Octagon Capital Advisors LP’s portfolio, making the stock its 3rd biggest holding. Octagon Capital Advisors LP’s holdings in Abivax were worth $75,384,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in ABVX. Nan Fung Trinity HK Ltd. lifted its holdings in Abivax by 11.8% in the 4th quarter. Nan Fung Trinity HK Ltd. now owns 113,365 shares of the company’s stock valued at $15,288,000 after purchasing an additional 12,000 shares in the last quarter. Total Clarity Wealth Management Inc. acquired a new stake in Abivax during the 4th quarter worth $1,247,000. Tudor Investment Corp ET AL purchased a new stake in shares of Abivax during the third quarter worth $2,792,000. Brummer Multi Strategy AB purchased a new stake in shares of Abivax during the fourth quarter worth $1,939,000. Finally, Harbor Capital Advisors Inc. acquired a new stake in shares of Abivax in the fourth quarter valued at about $1,193,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on ABVX shares. BTIG Research raised their price target on shares of Abivax from $150.00 to $175.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Wedbush increased their price objective on shares of Abivax from $90.00 to $110.00 and gave the company a “neutral” rating in a report on Tuesday, June 30th. Wolfe Research set a $136.00 target price on shares of Abivax in a research note on Wednesday, June 3rd. Wall Street Zen upgraded Abivax from a “sell” rating to a “hold” rating in a report on Saturday, May 23rd. Finally, Citizens Jmp restated a “market outperform” rating and issued a $187.00 price target on shares of Abivax in a research report on Wednesday, July 1st. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $156.50.

Abivax Price Performance

Shares of ABVX stock opened at $125.70 on Monday. The firm’s 50-day moving average is $117.99 and its two-hundred day moving average is $118.22. Abivax SA Sponsored ADR has a 12 month low of $65.67 and a 12 month high of $148.83. The company has a market capitalization of $10.97 billion, a PE ratio of -24.13 and a beta of 0.87.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.23. The firm had revenue of $1.56 million during the quarter, compared to analysts’ expectations of $0.40 million. Sell-side analysts forecast that Abivax SA Sponsored ADR will post -3.4 EPS for the current year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.